INTRODUCTION {#sec1-1}
============

Cardiovascular disorders and major depression are two global problems, leading to a higher cost burden, loss of productivity, and an elevation in health services utilization.\[[@ref1]\] Both problems also result in a considerably lower quality of life, frequently with physical, psychological, and social components; lost productivity, and functional disability.\[[@ref2][@ref3]\] More importantly, not only do a notable number of patients who suffer from cardiovascular disorders experience major depression because of disease-related disability, a fear of being unable to work, and even an inability to communicate effectively with others (particularly with partners), the appearance of depression can lead to serious adverse events in those affected patients.\[[@ref4][@ref5][@ref6]\] Cardiovascular diseases should be carefully considered as a major adverse event.

Overall, the prevalence of depression in patients with cardiovascular diseases has been reported to be widely varied. About two-thirds of these patients are diagnosed with a mild form of depression, especially those who experience acute myocardial infarction while major debilitating depression can be found in about 15% of these patients.\[[@ref7][@ref8]\] The prevalence of major depression has been reported to be even higher in chronic heart failure, so depending on the level of physical dysfunction, it can range between 10% in heart failure patients with mild physical dysfunction to 40% in those with severe physical impairment.\[[@ref9]\] The importance of this issue is that depression has been well identified as an independent determinant in lowering patients' survival.

Given the importance of the role of depression in predicting the outcome of cardiovascular disorders, current medications for treating depression in these patients are taken into consideration. In this regard, employing newer antidepressants may lead to adverse cardiovascular consequences.\[[@ref10]\] Thus, the choice of these drugs should be considered based on their purported mechanism of action and their related side effects.\[[@ref10]\] It seems that the interactive role of both cardiovascular disorders and antidepressants on triggering or inhibiting hormonal pathways, including serotonin, norepinephrine, and dopamine, may account for these effects.\[[@ref11][@ref12]\]

One of the main drug groups commonly used to treat depression that affects cardiovascular function is selective serotonin reuptake inhibitors (SSRIs), which were primarily introduced in 1980.\[[@ref13]\] These drugs are commonly prescribed in different disease conditions because of their high efficacy, cost-benefit, ease of use, and favorite side effects, especially on the cardiovascular system.\[[@ref14][@ref15]\] Furthermore, SSRI-related fatality events and life-threatening complications have been shown to be the lowest when compared to other types of antidepressants.\[[@ref16]\] Cardiac death related to administrating SSRIs has rarely been reported.\[[@ref17]\] In this regard, the most common cardiovascular-related side effects of SSRIs include mild bradycardia and hypotension, mild QRS prolongation, and first-degree cardiac block.\[[@ref18]\] Rarely, vasoconstriction following the administration of high-dose SSRIs may predispose the patient to myocardial infarction.\[[@ref19]\]

Based on the previous studies, the effect of SSRIs on cardiovascular diseases is controversy and regarding the high prevalence of both cardiovascular diseases and the use of SSRIs, and the mentioned concomitant conditions, this study aimed to systematically review the published findings in the use of SSRIs and the risk for cardiac events.

MATERIALS AND METHODS {#sec1-2}
=====================

Search strategy {#sec2-1}
---------------

To find primary studies published electronically up to February 2014, we searched the databases on the Web of Science, PubMed, Scopus, Cochrane Database, CINAHL, Index Copernicus, and Google Scholar. We included articles limited to full studies in the English language. For our following raised question, "In depressed subjects using SSRIs, what would be the cardiovascular effects after the chronic use of this drug group?" we conducted our search using the keywords "cardiovascular," "event," "outcome," "side effects," and "selective serotonin reuptake inhibitors."

Studies selection {#sec2-2}
-----------------

The titles and abstracts of relevant papers were studied and extracted to an EndNote X6 by a single last year student of medicine and co-author of this study. Two independent cardiologists being as the coauthors of this study further reviewed and screened the titles and abstracts of the papers identified for their potential relevance based on the inclusion criteria and assessed the full text for including them in the review. In the case of disagreement, the discrepancy was determined in consultation with a third coauthor.

Study inclusion eligibility {#sec2-3}
---------------------------

We limited our findings based on the following inclusion criteria:

Articles in English,Full-text availability,Experimental studies.

Study exclusion eligibility {#sec2-4}
---------------------------

Exclusion criteria were as follows:

Editorials,Duplicate studies,Results of a paper that was not clear.

The identified abstracts were then collected and coded by each investigator. The full texts of potentially relevant studies were then pulled, and the methods and results sections were reviewed for trial design and the reporting of study end points. Each trial was accessed across the following criteria: Allocation sequence generation, allocation concealment, blinding, complete outcome data reporting, selective outcome reporting, and other apparent biases.\[[@ref20][@ref21]\] The main reviewed outcome was cardiovascular events following the use of SSRIs. Among 150 studies reviewed based on the included keywords, 17 met the study criteria and were finally reviewed.

The pooled relative risk (RR) was calculated for each outcome using the inverse-variance method for random effects as well as for fixed effects.\[[@ref22]\] The data heterogeneity was assessed using the Cochrane Q-test via a Chi-square test and quantified with the *I^2^* test.\[[@ref23]\] We used the log RR as the dependent variable. The log RR standard error was used to measure the within-study variability, and the residual maximum likelihood method was used to estimate between the study variance. All analyses were performed using STATA version 11.0 (StataCorp; College Station, TX, USA) and CMA software version 2.2.064 (Borenstein, Hedges, Higgins, and Rothstein; Biostat; Englewood, NJ, USA).

RESULTS {#sec1-3}
=======

Study assessment {#sec2-5}
----------------

Among 150 abstracts retrieved from the initial search, 17 studies were extracted for review based on the inclusion criteria \[[Figure 1](#F1){ref-type="fig"}\]. Among the 17 studies, five articles published follow-up data for the effect of SSRIs on cardiovascular events with a range of 30-day to 1 year. Moreover, among the 17 studies, 6 were review articles \[[Table 1](#T1){ref-type="table"}\]. The inter-reviewer agreement for the study selection was high, with *k* = 0.93, and no obvious heterogeneity was identified among the included studies (*χ*^2^ = 6.55, *P* for *χ*^2^ = 0.428; *I*^2^ = 6.6%). Overall, 66,660 included patients were identified as being treated with various types of SSRIs, including fluoxetine, sertraline, citalopram, escitalopram, paroxetine, sibutramine, and benfluorex. Contradictory results were revealed regarding the beneficial or toxic effects of SSRIs on the cardiovascular system. However, the studies have claimed that both the cardioprotective and cardio-toxicity of these types of drugs led to either improved patient survival or deteriorating heart failure, respectively. Therefore, beneficial and deleterious effects of SSRIs on cardiovascular events are mentioned separately in the following sections:
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Beneficial effects of selective serotonin reuptake inhibitors {#sec2-6}
-------------------------------------------------------------

With respect to the beneficial effects of SSRIs on the cardiovascular system, one of the main protective roles of the new generations of SSRIs is related to their effects on inhibiting platelet aggregation as well as improving serotonin-related platelet abnormalities, leading to a reduction in cardiovascular mortality and morbidity.\[[@ref24]\] In this regard, pathophysiological studies could demonstrate that the inhibitory effects of SSRIs, especially citalopram, on platelet aggregation and the progression of atherosclerosis can be related to the inhibition of collagen, thrombin, and U46619.\[[@ref25][@ref26]\] In addition, sibutramine, as new form of SSRI, has been shown to be an anti-atherogenic agent that can improve insulin resistance, glucose metabolism, dyslipidemia, and inflammatory markers, mostly resulting from its effect on weight loss.\[[@ref27]\] Another beneficial effect of some forms of SSRIs, such as sertraline, is its anti-inflammatory effect as well as improving endothelial function. Some studies show that the use of sertraline effectively reduces inflammatory markers, including C-reactive protein and interleukin-6 (IL-6), after a 20-week administration of this drug led to the improvement of the endothelium-mediated dilation marker.\[[@ref28]\] Some authors emphasized a similar role of some SSRIs, such as fluoxetine, on calcium channel blockers, so that fluoxetine could reduce \[Ca^2+^\]i and the tonicity of arteriolar smooth muscle, likely by interfering with Ca^2+^ entry, which can act as a therapeutic element in cardiovascular disease groups.\[[@ref29][@ref30]\] In a recent review article, SSRIs were concluded to be the safest antidepressants drugs, especially those with cardioprotective effects on ventricular function as well as cardiac conductive system.\[[@ref31]\]

Deleterious effects {#sec2-7}
-------------------

Along with the beneficial effects of SSRIs on the cardiovascular system, various side effects of SSRIs via different pathways have been reported to result in an increased risk for early and long-term mortality and morbidity. One of the most important cardiovascular side effects of SSRIs includes cardiac arrhythmias. Although this side effect occurs in about 4% of cardiovascular patients, it can be well tolerated in almost all patients.\[[@ref32]\] However, in rare cases, some serious arrhythmias, such as torsade de pointes and QT prolongation, can also occur following the use of some SSRIs, such as fluoxetine, sertraline, and citalopram.\[[@ref33][@ref34]\]

The occurrence of other types of cardiac arrhythmias, including atrial fibrillation and bradycardia after the administration of SSRIs, particularly after a fluoxetine overdose, has also been pointed out. These arrhythmic events can be explained by inhibiting cardiac Ca^2+^ and Na^+^ channels by fluoxetine, especially in chronic treatment with this drug.\[[@ref35]\] In this regard, the inhibition of cardiac Ca^2+^, Na^+^, and K^+^ and vascular Ca^2+^ channels by SSRI scan explain the cardiovascular side effects occasionally observed with these drugs during chronic treatment.\[[@ref35]\]

Another important effect of SSRIs involving pathophysiological pathways in cardiovascular disorders is the interaction between some SSRIs, such as escitalopram, citalopram, and paroxetine, and some cardiovascular drugs such as statins. The main pathophysiology of this effect is related to the inhibitory effect of these drugs on the cytochrome P450 metabolic pathways, triggering statin side effects such as myopathy and rhabdomyolysis.\[[@ref36]\] Different drug-induced behaviors have been pointed out in the occurrence of SSRI-induced syncope, for example, some authors show the protective effects of SSRIs on neurocardiogenic vasovagal syncope. In one clinical trial, after 1 month of treatment with paroxetine in patients with vasovagal syncope, spontaneous syncope was observed in 17.6% of the patients in the paroxetine group as compared to 52.9% in the placebo group.\[[@ref37]\] In parallel with the clinically adverse consequences of administrating SSRIs, some echocardiographic assessments have focused on the structural cardiovascular changes following the use of these drugs. Some evidence has shown an association between using SSRIs and changes in the right ventricular volume and diameter. More interestingly, these changes might be different in men and women so that a higher right ventricular end-diastolic volume among women and larger right ventricular end-systolic volume in both sexes were revealed following the use of SSRIs.\[[@ref38]\] Despite some evidence on the effects of SSRIs on the structural and functional changes of heart valves, especially mitral and aortic regurgitation, recent studies could not demonstrate morphological abnormalities in these valves.\[[@ref39]\]

DISCUSSION {#sec1-4}
==========

In this review, we attempted to assess the adverse effects of SSRIs on the cardiovascular system. According to the recent reports, cardiac arrhythmias are the most frequent cardiovascular events, constituting one-third of the most commonly encountered adverse reactions following the consumption of SSRIs. In this context, tachycardia, long QT syndrome, and torsade de pointes are the most common events.\[[@ref40][@ref41]\] In other reports, mild bradycardia, dysrhythmia, syncope, and orthostatic hypotension have been found to be associated with SSRI consumption.\[[@ref35]\] Although arrhythmic events may occur in a notable number of patients using SSRIs, these events are usually mild and tolerable, not leading to a discontinuation of the use of that drug. Nevertheless, taking the inappropriate SSRI may lead patients to more complicated treatments as a result of the antidepressants' complications.\[[@ref42][@ref43]\]

Regarding, the association between SSRI use and atherosclerotic development, it has been primarily demonstrated that there is a direct association between SSRI use and an increased serum level of inflammatory biomarkers, such as IL-6 and tumor necrosis factor-alpha. In some trials, higher levels of these markers in depressed SSRI-resistant patients, compared with healthy controls, have been found. Thus, it has been suggested that treatment with SSRIs can induce the production of these proinflammatory cytokines.\[[@ref44][@ref45][@ref46][@ref47][@ref48]\] Moreover, a higher incidence of cardiac atherosclerotic events in those patients with a history of SSRI use has been revealed. According to the central role of inflammatory processes in developing coronary atherosclerosis, the link between the use of SSRIs and the development of atherosclerotic lesions can be predicted.

Although the initial evidence of SSRI effects on the morphological changes in heart valves was presented in the mid-1980s by Mast *et al*.,\[[@ref49]\] recent reports by Maréchaux *et al*.\[[@ref39]\] show no increasing risk for heart valve disease following the use of SSRIs. It has previously been demonstrated that using drugs with a high affinity for the 5-hydroxytryptamine receptor 2B (5-HT~2B~) receptor, such as fenfluramine, can result in drug-induced fibrotic valvular disease via the up-regulation of some genes involving the proliferation and stimulation of valvular interstitial cells. This occurs via various intracellular pathways, such as the G protein-mediated activation of protein kinase C, SRC protein, extracellularly regulated kinases 1 and 2, and transforming growth factor beta-receptor activation.\[[@ref50]\] However, SSRIs have no 5-HT~2B~ agonist properties. Furthermore, although stimulating the 5-HT~1B~ receptors can induce the secretion of collagen by cardiac myofibroblasts, this receptor to SSRIs has no role in developing valvulopathy;\[[@ref51]\] therefore, no heart valve abnormalities after the use of SSRIs can be explained.

Reviewing the literature shows significant structural changes in the right ventricular dimensions as there are increased right ventricular end-systolic and end diastolic volumes following the chronic use of SSRIs; however, these changes may not result in changes in the right ventricular ejection fraction. Thus, it seems that right ventricular hypertrophy in the right ventricular volume without any change in the ejection fraction after using SSRIs can be adaptive, such as the heart changes in athletes. In this adaptation, the right ventricular hypertrophy can cause an increase in the capillary networks and oxygen transport.\[[@ref52][@ref53]\] In addition, the use of SSRIs has not only no deleterious effects on the right ventricular function, they can also protect right ventricular function due to their stimulating effects on protein oxidation in the right ventricle; however, this effect could not be shown in the left ventricle.\[[@ref54][@ref55][@ref56]\]

Some limitations of this study should be acknowledged. A wider range of keywords could be considered for our initial search so more articles could be extracted for analysis. In addition, some subgroup analysis such as sex-based differences due to inadequate data could not be performed. Moreover, studies with greater follow-ups would make our conclusion stronger. It is strongly recommended to conduct more studies particularly meta-analysis to study and compare other antidepressants with SSRIs for their effect on cardiovascular events.

CONCLUSION {#sec1-5}
==========

Overall, according to our systematic review, both beneficial and adverse cardiovascular events can be discovered following the chronic use of various types of SSRIs. The use of some types of SSRIs may prevent platelet adhesion and aggregation, controlling the cardiovascular risk profile, including hypertension, insulin resistance, and body weight as well as inhibiting inflammatory processes. However, the appearance of adverse cardiac events, including cardiac arrhythmias, syncope, increased right ventricular volume, and the production of proinflammatory cytokines leading to atherosclerotic development, have also been expected by chronically using some types of SSRIs.
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